早期应用血必净联合胸腺五肽治疗老年重症肺炎的临床价值研究

Clinical Value of Early Application of Xuebijing Combined with Thymopentin in the Treatment of Elderly Patients with Severe Pneumonia

目的治疗老年重症肺炎患者过程中,血必净联合胸腺五肽治疗方法的临床价值研究。方法随机在该院2016年3月-2018年3月收治的老年重症肺炎患者中抽取64例作为该次研究的主要对象。将64例患者随机分成两组,一组为对照组,人数为32例,并对患者实施血必净治疗;另一组为实验组,人数为32例,并对患者实施血必净联合胸腺五肽治疗。观察两组患者在CRP水平、白细胞总数以及体温等维度上面的差异。结果接受相应的治疗前,试验组与对照组患者在CRP水平、白细胞总数以及体温等指标分别为[(66.32±16.36)mg/L、(66.40±16.23)mg/L,(12.49±2.37)×10^9/L、(12.46±2.36)×10^9/L,(38.87±1.06)℃、(38.70±1.09)℃],两组间相比较(t=-0.16、0.46、-0.10,P=0.86、0.12、0.63,P>0.05)。而治疗后,试验组与对照组患者在CRP水平、白细胞总数以及体温等指标分别为(27.66±9.39)mg/L、(47.43±11.23)mg/L,(8.06±0.63)×10^9/L、(9.88±1.86)×10^9/L;(36.81±0.46)℃、(38.58±1.16)℃],两组间相比较(t=4.23、4.05、2.88,P=0.00、0.01、0.03,P<0.05);同时,两组患者的临床治疗总有效率相比,实验组患者的临床治疗总有效率为93.75%,明显更高(P<0.05)。结论早期应用血必净联合胸腺五肽治疗老年重症肺炎效果十分显著,能够加快患者病情转好的速度,值得在临床实践中大范围推广。

Objective To study the clinical value of Xuebijing combined with thymopentin in the treatment of elderly patients with severe pneumonia. Methods A total of 64 patients with severe pneumonia in our hospital from March 2016 to March 2018 were randomly selected as the main subjects of this study. A total of 64 patients were randomly divided into the control group (n=32, treated with Xuebijing) and the experimental group (n=32, treated with Xuebijing combined with thymopentin). The differences in CRP levels, total white blood cells, and body temperature were observed between the two groups. Results Before the treatment, the CRP level, total white blood cell count and body temperature of the experimental group and the control group were [(66.32±16.36) mg/L,(66.40±16.23) mg/L;(12.49±2.37)×10^9/L;(12.46±2.36)×10^9/L;(38.87±1.06)℃ and (38.70±1.09)℃](t=-0.16, 0.46,-0.10, P=0.86, 0.12, 0.63,P>0.05). After receiving the treatment, the data were[(27.66±9.39) mg/L,(47.43±11.23) mg/L;(8.06±0.63)×10^9/L,(9.88±1.86)×10^9/L;(36.81±0.46)℃ and (38.58±1.16)℃](t=4.23, 4.05, 2.88, P=0.00, 0.01, 0.03,P<0.05). At the same time, the total effective rate of clinical treatment in the experimental group was 93.75%, which was significantly higher than that in the control group(P<0.05). Conclusion The early application of Xuebijing combined with thymopentin in the treatment of elderly patients with severe pneumonia is very effective, which can speed up the recovery of patient's condition and is worthy of widespread promotion in clinical practice.